Profound Medical (TSE:PRN) Issues Earnings Results

Profound Medical (TSE:PRN) posted its quarterly earnings results on Thursday. The company reported C$0.37 earnings per share for the quarter, FiscalAI reports. Profound Medical had a negative return on equity of 86.83% and a negative net margin of 287.94%.The business had revenue of C$8.20 million for the quarter.

Profound Medical Stock Performance

PRN opened at C$8.90 on Friday. The company has a current ratio of 4.18, a quick ratio of 14.98 and a debt-to-equity ratio of 14.80. Profound Medical has a 12-month low of C$5.23 and a 12-month high of C$12.40. The firm has a 50 day moving average of C$10.18 and a two-hundred day moving average of C$8.72. The firm has a market capitalization of C$323.01 million, a PE ratio of -6.74 and a beta of 1.10.

Insider Buying and Selling at Profound Medical

In other Profound Medical news, insider Thomas Michael Tamberrino bought 13,908 shares of Profound Medical stock in a transaction that occurred on Tuesday, December 23rd. The stock was purchased at an average price of C$9.91 per share, with a total value of C$137,828.28. Following the completion of the acquisition, the insider directly owned 39,241 shares in the company, valued at approximately C$388,878.31. This trade represents a 54.90% increase in their position. 8.62% of the stock is owned by insiders.

About Profound Medical

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.